PL1963307T3 - Kwas 3-(4-{[4-(4-{[3-(3,3-dimetylo-1-piperydynylo)propyl]oksy}fenylo)-1-piperydynylo]karbonylo}-1-naftalenylo)propanowy lub propenowy jako antagonista receptorów H1 i H3 do leczenia zaburzeń zapalnych i/lub alergicznych - Google Patents
Kwas 3-(4-{[4-(4-{[3-(3,3-dimetylo-1-piperydynylo)propyl]oksy}fenylo)-1-piperydynylo]karbonylo}-1-naftalenylo)propanowy lub propenowy jako antagonista receptorów H1 i H3 do leczenia zaburzeń zapalnych i/lub alergicznychInfo
- Publication number
- PL1963307T3 PL1963307T3 PL06841477T PL06841477T PL1963307T3 PL 1963307 T3 PL1963307 T3 PL 1963307T3 PL 06841477 T PL06841477 T PL 06841477T PL 06841477 T PL06841477 T PL 06841477T PL 1963307 T3 PL1963307 T3 PL 1963307T3
- Authority
- PL
- Poland
- Prior art keywords
- piperidinyl
- naphthalenyl
- propanoic
- inflammatory
- propyl
- Prior art date
Links
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 title 2
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0525897A GB0525897D0 (en) | 2005-12-20 | 2005-12-20 | Compounds |
| GB0623217A GB0623217D0 (en) | 2006-11-21 | 2006-11-21 | Compounds |
| EP06841477A EP1963307B1 (en) | 2005-12-20 | 2006-12-19 | 3- (4- { [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl[0xy] phenyl) -1-piperidinyl carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
| PCT/EP2006/069943 WO2007071691A1 (en) | 2005-12-20 | 2006-12-19 | 3- (4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] 0xy} phenyl) -1-piperidinyl] carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1963307T3 true PL1963307T3 (pl) | 2010-05-31 |
Family
ID=37845266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06841477T PL1963307T3 (pl) | 2005-12-20 | 2006-12-19 | Kwas 3-(4-{[4-(4-{[3-(3,3-dimetylo-1-piperydynylo)propyl]oksy}fenylo)-1-piperydynylo]karbonylo}-1-naftalenylo)propanowy lub propenowy jako antagonista receptorów H1 i H3 do leczenia zaburzeń zapalnych i/lub alergicznych |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7989629B2 (pl) |
| EP (2) | EP2157087A1 (pl) |
| JP (2) | JP4445570B2 (pl) |
| KR (1) | KR20080087102A (pl) |
| AR (1) | AR058109A1 (pl) |
| AT (1) | ATE449769T1 (pl) |
| AU (1) | AU2006328512B2 (pl) |
| BR (1) | BRPI0620218A2 (pl) |
| CA (1) | CA2634391A1 (pl) |
| CR (1) | CR10102A (pl) |
| CY (1) | CY1110601T1 (pl) |
| DE (1) | DE602006010737D1 (pl) |
| DK (1) | DK1963307T3 (pl) |
| EA (1) | EA014354B1 (pl) |
| ES (1) | ES2337187T3 (pl) |
| IL (1) | IL191967A0 (pl) |
| MA (1) | MA30373B1 (pl) |
| NO (1) | NO20082695L (pl) |
| PE (1) | PE20071068A1 (pl) |
| PL (1) | PL1963307T3 (pl) |
| PT (1) | PT1963307E (pl) |
| SI (1) | SI1963307T1 (pl) |
| TW (1) | TW200730498A (pl) |
| WO (1) | WO2007071691A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| EP2448578A1 (en) | 2009-06-29 | 2012-05-09 | Glaxo Group Limited | New medical use |
| JP4785963B2 (ja) | 2009-10-09 | 2011-10-05 | キヤノン株式会社 | 固体撮像装置 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EA201692111A1 (ru) | 2014-05-12 | 2017-08-31 | Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний |
| KR101640756B1 (ko) | 2014-10-28 | 2016-07-19 | 이종찬 | 전동 드릴 장착용 내시경 캡 |
| US20200405728A1 (en) * | 2018-03-01 | 2020-12-31 | Ferox Therapeutics Llc | Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients |
| JP2023519585A (ja) | 2020-03-26 | 2023-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ウイルス感染を予防または治療するカテプシン阻害剤 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
| US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| JPH07509694A (ja) | 1992-05-14 | 1995-10-26 | ベイラー・カレッジ・オブ・メディシン | 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ |
| EP0957087B1 (en) | 1994-06-15 | 2002-12-04 | The Wellcome Foundation Limited | Intermediates useful in the preparation of enzyme inhibitors |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| CA2323771A1 (en) | 1998-03-14 | 1999-09-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| SI1305329T2 (sl) | 2000-08-05 | 2015-07-31 | Glaxo Group Limited | S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| DE60318188T2 (de) | 2002-03-26 | 2008-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| WO2003091204A1 (en) | 2002-04-25 | 2003-11-06 | Glaxo Group Limited | Phenethanolamine derivatives |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| WO2004018429A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US20060089375A1 (en) | 2002-09-16 | 2006-04-27 | Allen David G | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| CA2499150A1 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| AU2003274053A1 (en) * | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| RU2332400C2 (ru) | 2002-10-28 | 2008-08-27 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| US7465795B2 (en) * | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
| DE602007010118D1 (de) | 2006-04-20 | 2010-12-09 | Glaxo Group Ltd | 2-substituierte 4-benzylphthalazinonderivate als histamin-h1- und h3-antagonisten |
-
2006
- 2006-12-18 TW TW095147457A patent/TW200730498A/zh unknown
- 2006-12-18 PE PE2006001620A patent/PE20071068A1/es not_active Application Discontinuation
- 2006-12-18 AR ARP060105590A patent/AR058109A1/es not_active Application Discontinuation
- 2006-12-19 EA EA200801342A patent/EA014354B1/ru not_active IP Right Cessation
- 2006-12-19 ES ES06841477T patent/ES2337187T3/es active Active
- 2006-12-19 EP EP09176715A patent/EP2157087A1/en not_active Withdrawn
- 2006-12-19 DK DK06841477.0T patent/DK1963307T3/da active
- 2006-12-19 CA CA002634391A patent/CA2634391A1/en not_active Abandoned
- 2006-12-19 PL PL06841477T patent/PL1963307T3/pl unknown
- 2006-12-19 JP JP2008546432A patent/JP4445570B2/ja not_active Expired - Fee Related
- 2006-12-19 AU AU2006328512A patent/AU2006328512B2/en not_active Ceased
- 2006-12-19 AT AT06841477T patent/ATE449769T1/de active
- 2006-12-19 EP EP06841477A patent/EP1963307B1/en active Active
- 2006-12-19 DE DE602006010737T patent/DE602006010737D1/de active Active
- 2006-12-19 BR BRPI0620218-7A patent/BRPI0620218A2/pt not_active IP Right Cessation
- 2006-12-19 WO PCT/EP2006/069943 patent/WO2007071691A1/en not_active Ceased
- 2006-12-19 PT PT06841477T patent/PT1963307E/pt unknown
- 2006-12-19 US US12/158,185 patent/US7989629B2/en not_active Expired - Fee Related
- 2006-12-19 KR KR1020087015535A patent/KR20080087102A/ko not_active Ceased
- 2006-12-19 SI SI200630560T patent/SI1963307T1/sl unknown
-
2008
- 2008-06-05 IL IL191967A patent/IL191967A0/en unknown
- 2008-06-11 NO NO20082695A patent/NO20082695L/no not_active Application Discontinuation
- 2008-06-11 MA MA31023A patent/MA30373B1/fr unknown
- 2008-06-20 CR CR10102A patent/CR10102A/es not_active Application Discontinuation
-
2009
- 2009-06-12 JP JP2009140796A patent/JP2009235087A/ja active Pending
-
2010
- 2010-02-19 CY CY20101100170T patent/CY1110601T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1120265A1 (en) | 2009-03-27 |
| EA014354B1 (ru) | 2010-10-29 |
| EP1963307A1 (en) | 2008-09-03 |
| CY1110601T1 (el) | 2015-04-29 |
| DE602006010737D1 (de) | 2010-01-07 |
| MA30373B1 (fr) | 2009-05-04 |
| ATE449769T1 (de) | 2009-12-15 |
| EP2157087A1 (en) | 2010-02-24 |
| IL191967A0 (en) | 2008-12-29 |
| US7989629B2 (en) | 2011-08-02 |
| SI1963307T1 (sl) | 2010-03-31 |
| NO20082695L (no) | 2008-09-16 |
| AU2006328512A1 (en) | 2007-06-28 |
| WO2007071691A1 (en) | 2007-06-28 |
| CA2634391A1 (en) | 2007-06-28 |
| JP2009235087A (ja) | 2009-10-15 |
| JP2009520001A (ja) | 2009-05-21 |
| US20080312280A1 (en) | 2008-12-18 |
| ES2337187T3 (es) | 2010-04-21 |
| BRPI0620218A2 (pt) | 2011-11-01 |
| PE20071068A1 (es) | 2007-12-13 |
| EA200801342A1 (ru) | 2008-12-30 |
| JP4445570B2 (ja) | 2010-04-07 |
| PT1963307E (pt) | 2010-03-03 |
| DK1963307T3 (da) | 2010-04-06 |
| AU2006328512B2 (en) | 2011-06-23 |
| KR20080087102A (ko) | 2008-09-30 |
| TW200730498A (en) | 2007-08-16 |
| CR10102A (es) | 2008-09-22 |
| AR058109A1 (es) | 2008-01-23 |
| EP1963307B1 (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024025I2 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4- ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
| IL183827A0 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| IL191967A0 (en) | 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]oxy}phenyl)-1-piperidinyl]carbonyl]-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders | |
| ZA200702392B (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders | |
| ZA200804030B (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof | |
| EP1874286A4 (en) | METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE | |
| DE602006010243D1 (de) | 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen | |
| EP1893216A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| DE602007010303D1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| IL187302A0 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| IL191283A (en) | Compositions for treating eye irregularities | |
| PL2444079T3 (pl) | Kompozycje i sposoby leczenia chorób oczu | |
| ZA200804742B (en) | Compounds for the treatment of inflammatory disorders and microbial diseases | |
| IL191637A0 (en) | Compounds for the treatment of inflammatory disorders and microbial diseases | |
| UA108087C2 (uk) | Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду | |
| EP1940441A4 (en) | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS | |
| ZA200803440B (en) | Compounds for the treatment of metabolic disorders | |
| ZA200806782B (en) | Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4{[R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylaminoimethyl]}-5-methoxyphenyl-carbamoyl) ethyl] piperidin-4-YL ester and its use for the treatment of pulmonary disorders | |
| IL191293A0 (en) | Compositions for regulating metabolic disorders and methods of use thereof | |
| IL189009A0 (en) | Methods and compositions for the treatment of neuropathies and related disorders | |
| SI1968949T1 (sl) | Izboljšani postopek za pripravo soli 4-(benzimidazolilmetilamino)-benzamidov | |
| EP1814575A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SUFFERING | |
| IL191537A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| EP2262514A4 (en) | MEDIUM TO PROMOTE SECRETION AND / OR SUPPRESSION OF ACCEPTANCE OF ADIPONECTIN | |
| WO2008099887A1 (ja) | メチル ｎ－［３－（６，７－ジメトキシ－２－メチルアミノキナゾリン－４－イル）フェニル］テレフタラミックアシッドの結晶、非晶質体または塩 |